Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation

In this single-center analysis, PTCy-based GVHD prophylaxis demonstrated superior chronic GVHD-free survival, significantly reduced NRM, and trends toward higher GRFS compared with TAC/MTX in MAC HLA-matched HCT for acute leukemia. However, a signal of increased relapse, particularly among patients with detectable MRD before HCT, warrants further investigation. Integrating enhanced anti-leukemic strategies with PTCy platforms may optimize long-term outcomes.